Features of early-onset familial Alzheimer’s disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Alzheimer’s disease (AD) is the most common form of dementia in clinical practice. The early-onset AD is difficult to diagnose due to its rare occurrence. This article presents an up-to-date review of data on the incidence, pathomorphology of the brain, clinical picture, diagnosis and pharmacotherapy of early-onset AD. Particular attention is paid to the genetic aspects of AD with autosomal dominant mode of inheritance.

Full Text

Restricted Access

About the authors

Yu. E Cherdantseva

I.M. Sechenov First Moscow State University (Sechenov University)

A. S Orlova

I.M. Sechenov First Moscow State University (Sechenov University)

Elena S. Akarachkova

International Society “Stress Under Control"

Email: nevroius@mail.ru
MD, President

A. Yu Alekseeva

I.M. Sechenov First Moscow State University (Sechenov University)

M. A Akulov

N.N. Burdenko NMRC of Neurosurgery

V. A Dadaeva

National Medical Research Center for Preventive Medicine

V. A Orlov

PCH № 4 n.a. P.B. Gannushkin of the Moscow Healthcare Department

References

  1. Науменко А.А., Громова Д.О., Трофимова Н.В., Преображенская И.С. Диагностика и лечение болезни Альцгеймера. Неврология, нейропсихиатрия, психосоматика. 2016;8(4):91-7.
  2. Panegyres P.K., Chen H.Y., et al. Early-onset Alzheimer's disease: a global cross-sectional analysis. Eur. J. Neurol. 2014;21(9):1149-54.
  3. Alzheimer's association. URL: https://www.alz.org/. 2018.
  4. Ватолина М.А. Проблемы оценки смертности от болезни Альцгеймера в России. Здравоохранение Российской Федерации. 2015;59(4):20-4.
  5. Seltzer B., Sherwin I. A comparison of clinical features in early- and late-onset primary degenerative dementia. One entity or two? Arch. Neurol. 1983;40(3):143-46.
  6. Dorszewska J., Prendecki M., Oczkowska A., et al. Molecular Basis of Familial and Sporadic Alzheimer's Disease. Curr. Alzh. Res. 2016;13(9):952-63.
  7. Day G.S., Musiek E.S., Roe C.M., et al. Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. JAMA. Neurol. 2016;73(9):1125-32.
  8. Abbate C., Arosio B., Cantatore A., et al. Familial late-onset Alzheimer's disease: description of an Italian family with four affected siblings and one case of early-onset dementia in the preceding generation. Aging. Clin. Exp. Res. 2016;28(5):991-95.
  9. Shea Y.F., Chu L.W., Chan A.O., et al. A systematic review of familial Alzheimer's disease: Differences in presentation of clinical features among three mutated genes and potential ethnic differences. J. Formos. Med. Assoc. 2016;115(2):67-75.
  10. Dai M.H., Zheng H., Zeng L.D., Zhang Y The genes associated with early-onset Alzheimer's disease. Oncotarget. 2017;15:15132-43.
  11. Wu L., Rosa-Neto P., Hsiung G.Y., et al. Early-onset familial Alzheimer's disease (EOFAD). Can. J. Neurol. Sci. 2012;39(4):436-45.
  12. Müller S., Preische O., Sohrabi H.R., et al. Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzh. Dement. 2018;21:1552-60.
  13. Niu F., Yu S., Zhang Z., et al. Novel mutation in the PSEN2 gene (N141Y) associated with early-onset autosomal dominant Alzheimer's disease in a Chinese Han family. Neurobiol. Aging. 2014;35(10):2420.
  14. Яузина Н.А., Комлева Ю.К., Салмина А.Б. и др. Эпидемиология болезни Альцгеймера в мире. Неврологический журнал. 2012;17:32-7. [Yauzina N.A., Komleva Yu.K., Salmina A.B., et al. Epidemiology of Alzheimer's disease in the world. Nevrologicheskiizhurnal. 2012;17:32-7. (in Russ.)].
  15. Гаврилова С.И., Колыхалов И.В. Разработка стандарта терапии болезни Альцгеймера. Современная терапия в психиатрии и неврологии. 2012;1:5-
  16. [Gavrilova S.i., Kolykhalov i.V. Development of a standard Alzheimer's disease therapy. Sovremennaya terapiya v psikhiatrii i nevrologii. 2012;1:5-10. (in Russ.)].
  17. Wu L., Rosa-Neto P., Hsiung G.Y., et al. Early-onset familial Alzheimer's disease (EOFAD). Can. J. Neurol. Sci. 2012;39(4):436-45.
  18. Cacace R., Sleegers K., Van Broeckhoven C. Molecular genetics of early-onset Alzheimer's disease revisited. Alzh. Dement. 2016;12(6):733-48.
  19. Колыхалов И.В. Некогнитивные психические расстройства при болезни Альцгеймера: эпидемиологические, клинико-психопатологические, прогностические и терапевтические аспекты. Дисс. докт. мед. наук. М., 2016.
  20. Белоусов Ю.Б., Зырянов С.К., Белоусов Д.Ю., Бекетов А.С. Клинико-экономические аспекты терапии болезни Альцгеймера в России. Качественная клиническая практика. 2009;1:3-
  21. Комлева Ю.К., Кувачева Н.В., Лопатина О.Л. Современные представления о патогенезе болезни Альцгеймера: новые подходы к фармакотерапии (обзор). Современные технологии в медицине. 2015;7(3):138-48.
  22. Hersi M., Irvine B., Gupta P., et al. Risk factors associated with the onset and progression of Alzheimer's disease: A systematic review of the evidence. Neurotoxicol. 2017;6:143-87.
  23. Wingo T.S., Lah J.J., Levey A.I., Cutler D.J. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch. Neurol. 2012;69:59-64.
  24. Jarmolowicz A.I., Chen H.Y., Panegyres P.K. The Patterns of Inheritance in Early-Onset Dementia: Alzheimer's Disease and Frontotemporal Dementia. Am. J. Alzh. Dis. Other Demen. 2014;30:299-306.
  25. Janssen J.C., Beck J.A., Campbell T.A., et al. Early onset familial Alzheimer's disease: mutation frequency in 31 families. Neurol. 2003;60:235-39.
  26. Alzforum networking for a cure. URL: https://www. alzforum.org/mutations. 2018.
  27. Ikeuchi T., Kaneko H., Miyashita A., et al. Mutational analysis in early-onset familial dementia in the Japanese population. The role of PSEN1 and MAPT R406W mutations. Dement. Geriatr. Cogn. Disord. 2008;26:43-9.
  28. Barber I.S., Braae A., Clement N., et al. Mutation analysis of sporadic early-onset Alzheimer's disease using the NeuroX array. Neurobiol. Aging. 2017;49:215.
  29. Lanoiselée H.M., Nicolas G., Wallon D., et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS. Med. 2017;14(3):e1002270.
  30. Shao W., Peng D., Wang X. Genetics of Alzheimer's disease: From pathogenesis to clinical usage. J. Clin. Neurosci. 2017;45:1-8.
  31. Liu C.C., Liu C.C., Kanekiyo T., et al. Apolipoprotein E. and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013;9(2):106-18.
  32. Alzheimer's Association. Alzheimer's disease facts and figures. Alzh. Dement. 2016;12(4):459-509.
  33. Rajah M.N., Wallace L.M.K., Ankudowich E., et al. Family history and APOE4 risk for Alzheimer's disease impact the neural correlates of episodic memory by early midlife. Neuroimage Clin. 2017;14:760-74.
  34. Zhu J.B., Tan C.C., Tan L., Yu J.T. State of Play in Alzheimer's Disease Genetics. J. Alzh. Dis. 2017;58(3):631-59.
  35. Butters M.A., Sweet R.A., Mulsant B.H., et al. APOE is associated with age-of-onset, but not cognitive functioning, in late-life depression. Int. J. Geriatr. Psychiatry. 2003;18(1):1075-81.
  36. Bateman R.J., Aisen P.S., De Strooper B., et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzh. Res. Ther. 2011;2:35.
  37. Albert M.S., DeKosky S.T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzh. Dement. 201;7:270-79.
  38. McKhann G.M., Knopman D.S., Chertkow H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzh. Dement. 2011;7:263-69.
  39. Sperling R.A., Aisen P.S., Beckett L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzh. Dement. 2011;7:280-92.
  40. De la Torre J.C. Three postulates to help identify the cause of Alzheimer's disease. J. Alzh. Dis. 2011;24:657-68.
  41. Glass C.K., Saijo K., Winner B., et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918-34.
  42. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Sci. 2002;297:353-56.
  43. Bettens K., Sleegers K., Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum. Mol. Genet. 2010;19:4-11.
  44. Esler W.P., Wolfe M.S. A portrait of Alzheimer secretases - new features and familiar faces. Sci. 2001;293:1449-54.
  45. Citron M., Oltersdorf T., Haass C., et al. Mutation of the beta-amyloid precursor protein in familial Alzheimers-disease increases betaprotein production. Nature. 1992;360:672-74.
  46. Suzuki N., Cheung T.T., Cai X.D., et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Sci. 1994;26:1336-40.
  47. Steiner H. Uncovering gamma-secretase. Curr. Alzh. Res. 2004;1:175-81.
  48. Преображенская И.С. Современные подходы к диагностике и лечению болезни Альцгеймера. Медицинский совет. 2017;10:26-31.
  49. Jan A.T., Azam M., Rahman S., et al. Perspective Insights into Disease Progression, Diagnostics, and Therapeutic Approaches in Alzheimer's Disease: A Judicious Update. Front Aging Neurosci. 2017;9:356.
  50. Maccioni R.B., Munoz J.P., Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res. 2001;32(5):367-81.
  51. Freudenberg-Hua Y., Li W., Davies P. The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease-A Narrative Review. Front. Med. (Lausanne). 2018;5:108.
  52. Kong D., Giovanello K.S., Wang Y., et al. Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data. J. Alzh. Dis. 2015;46(3):695-702.
  53. Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Деменции. 3-е изд. Руководство для врачей. М., 2011. 272 с.
  54. Науменко А.А., Вахнина Н.В. Болезнь Альцгеймера под маской инсульта. Неврология, нейропсихиатрия, психосоматика 2016;8(2):100-6.
  55. Penninkilampi R., Brothers H.M., Eslick G.D. Safety and Efficacy of Anti-Amyloid-ß Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis. J. Neuroimmune Pharmacol. 2017;12(1):194-203.
  56. Wang C.H., Wang L.S., Zhu N. Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs as Alzheimer's disease therapies: an updated umbrella review of systematic reviews and meta-analyses. Eur. Rev. Med. Pharmacol. Sci. 2016;20(22):4801-17.
  57. Matsunaga S., Kishi T., Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 2014;28:1-11.
  58. Matsunaga S., Kishi T., Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS. One. 2015;10(4):e0123289.
  59. Kishi T, Matsunaga S., Oya K., et al. Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. J. Alzh. Dis. 2017;60(2): 401-25.
  60. Jiang J., Jiang H. Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials. Neurol. Sci. 2015;36(9):1633-41.
  61. Liu C.S., Ruthirakuhan M., Chau S.A., et al. Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments. Curr. Alzh. Res. 2016;13(10):1134-44.
  62. Panza F., Solfrizzi V., Imbimbo B.P., et al. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Exp. Rev. Clin. Immunol. 2014;10(3):405-19.
  63. Lannfelt L., Relkin N.R., Siemers E.R. Amyloid-β-directed immunotherapy for Alzheimer's disease. J. Intern. Med. 2014;275(3):284-95.
  64. Panza F., Solfrizzi V., Imbimbo B.P., et al. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. Exp. Rev. Neurother. 2014;14(9):973-86.
  65. Ostrowitzki S., Lasser R.A., Dorflinger E., et al. A phase III randomized trial of gacntenerumab in prodromal Alzheimer's disease. Alzh. Res. Ther. 2017;9(1):95.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies